anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.92 [0.83, 1.01]< 18%23 studies (23/-)96.3 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical deterioration 0.68 [0.52, 0.89]< 121%7 studies (7/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement 1.17 [1.02, 1.36]> 136%11 studies (11/-)98.5 %some concernlow moderateimportant-
clinical improvement (14-day) 1.16 [0.84, 1.60]> 10%2 studies (2/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.23 [0.87, 1.74]> 10%2 studies (2/-)88.1 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.85 [0.56, 1.29]> 10%1 study (1/-)22.3 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.79 [0.63, 5.11]> 179%2 studies (2/-)86.3 %some concernnot evaluable moderateimportant-
death or ventilation 0.81 [0.60, 1.07]< 134%6 studies (6/-)93.0 %some concernserious moderateimportant-
hospital discharge 1.09 [1.01, 1.18]> 17%4 studies (4/-)98.8 %some concernnot evaluable moderateimportant-
ventilation 0.90 [0.54, 1.51]< 10%5 studies (5/-)64.9 %some concernnot evaluable moderateimportant-
ICU admission 0.43 [0.20, 0.96]< 158%5 studies (5/-)98.0 %some concernnot evaluable moderatenon important-
time to recovery 1.06 [0.77, 1.46]> 10%1 study (1/-)63.8 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 1.21 [0.75, 1.95]< 14%5 studies (5/-)21.7 %some concernnot evaluable moderateimportant-
superinfection 0.79 [0.56, 1.11]< 10%2 studies (2/-)91.1 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.